-
Product Insights
Mycosis Fungoides Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Mycosis Fungoides - Global Clinical Trials Review, 2025" provides an overview of Mycosis Fungoides Clinical trials scenario. This report provides top line data relating to the clinical trials on Mycosis Fungoides. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Glaucoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Glaucoma - Global Clinical Trials Review, 2025" provides an overview of Glaucoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Glaucoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Multiple Sclerosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Multiple Sclerosis - Global Clinical Trials Review, 2025" provides an overview of Multiple Sclerosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Hypocobalaminemia (Vitamin B12) Deficiency Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Hypocobalaminemia (Vitamin B12) Deficiency - Global Clinical Trials Review, 2025" provides an overview of Hypocobalaminemia (Vitamin B12) Deficiency Clinical trials scenario. This report provides top line data relating to the clinical trials on Hypocobalaminemia (Vitamin B12) Deficiency. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Sector Analysis
Endometriosis in 68-Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2034
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Endometriosis market. Across the 68 markets, sales in the endometriosis market were $1.5 billion in 2024, growing to $4.6 billion in 2034. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 37.5% and 45.9% in 68-market sales in 2024 and 2034, respectively.
-
Sector Analysis
Chronic Kidney Disease Anemia Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034
This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the CKD Anemia market through 2034. There will be an overall increase in the diagnosed prevalent cases of CKD Anemia in the 7MM across the forecast period. Across the 7MM, the mainstay treatment for CKD Anemia involves the use of ESAs and iron therapies. Significant clinical and environmental unmet needs remain in the CKD Anemia market. The late-stage CKD anemia pipeline consists of 2 agents....
-
Sector Analysis
Head and Neck Squamous Cell Carcinoma Epidemiology Analysis and Forecast to 2034
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group consisting of cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate, and other parts of mouth (International Statistical Classification of Diseases and Related Health Problems 10th Revision [ICD-10] code = C00–C06); the salivary glands (ICD-10 code = C07–C08); the pharynx, including the tonsil, oropharynx, nasopharynx, pyriform fossa, hypopharynx, other mouth/pharynx (ICD-10 code = C09–C14); the nose, sinuses, and related structures (ICD-10 code = C30–C31), and...
-
Sector Analysis
Multiple Sclerosis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the 7 major markets and provides an Excel-based forecast model for the Multiple Sclerosis (MS) market through 2034. GlobalData estimated that the PD market was $22.0 billion across the 7MM in 2024. By the end of the forecast period in 2033, sales across these markets will reach $25.9 billion, increasing at a compound annual growth rate (CAGR) of 1.7%. The major drivers of growth in the PD market will be the launch of new disease modifying therapies...
-
Sector Analysis
Endometriosis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Endometriosis market through 2034. GlobalData estimates the 2024 sales for the endometriosis market at approximately $938.0 million across the 7MM, encompassing the US, the 5EU, and Japan. By 2034, GlobalData expects the overall market to grow at a compound annual growth rate (CAGR) of 10.3% to reach sales of $2.5 billion over the 10-year period. The US market will grow...
-
Sector Analysis
Psoriatic Arthritis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This new set to update and replace the previous psoriatic arthritis market analysis publication, Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028 (January 2020, GDHC186PIDR), which covered the forecast period 2018–28. This new publication covers the psoriatic arthritis market over the forecast period of 2023-33. GlobalData estimated the total psoriatic arthritis market to be valued at $5.1 billion across the 8MM, with the US accounting for 80.4% of the market. The five major GlobalData estimated the value of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.